吡非尼酮的多方面作用及其新靶点。
The multifaceted role of pirfenidone and its novel targets.
作者信息
Macías-Barragán José, Sandoval-Rodríguez Ana, Navarro-Partida Jose, Armendáriz-Borunda Juan
机构信息
Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Guadalajara, Mexico.
出版信息
Fibrogenesis Tissue Repair. 2010 Sep 1;3:16. doi: 10.1186/1755-1536-3-16.
BACKGROUND
Pirfenidone (PFD) is a molecule that exhibits antifibrotic properties in a variety of in vitro and animal models of lung, liver and renal fibrosis. These pathologies share many fibrogenic pathways with an abnormal fibrous wound-healing process; consequently, tissue repair and tissue regeneration-regulating mechanisms are altered.
OBJECTIVE
To investigate the usefulness of PFD as an antifibrotic agent in clinical and experimental models of fibrotic disease.
CONCLUSIONS
There is a growing understanding of the molecular effects of PFD on the wound healing mechanism, leading to novel approaches for the management of fibrosis in lung, liver and renal tissues. Although the optimum treatment for fibrosis remains undefined, it is possible that combined therapeutic regimens that include this wide-application molecule, pirfenidone, could offer a useful treatment for fibrotic disease.
背景
吡非尼酮（PFD）是一种在多种肺、肝和肾纤维化的体外及动物模型中均表现出抗纤维化特性的分子。这些病症与异常纤维性伤口愈合过程共享许多纤维化途径；因此，组织修复和组织再生调节机制发生改变。
目的
研究PFD作为抗纤维化药物在纤维化疾病临床及实验模型中的效用。
结论
人们对PFD对伤口愈合机制的分子效应的认识不断加深，从而产生了用于治疗肺、肝和肾组织纤维化的新方法。尽管纤维化的最佳治疗方案仍不明确，但包含这种广泛应用的分子——吡非尼酮的联合治疗方案可能为纤维化疾病提供有效的治疗方法。
Zotero 插件